Company News in the Life Science Industry

»

Reset 

Research from XJTLU advances RNA modification mapping

SUZHOU, China, March 21, 2019 /PRNewswire/ -- Researchers from Xi'an Jiaotong-Liverpool University have completed a high-resolution prediction of the whole-transcriptome m6A RNA modification, successfully creating the world's most accurate map of the m6A epitranscriptome.

Read more ››
By: PR Newswire Association LLC. - 21 Mar 2019

Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials

HANGZHOU, China, March 21, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today announced that it has received a clearance from the National Medical Products Administration (NMPA) of China for initiating the open-label, randomized, multicenter,... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019

BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors

LUND, Sweden , March 21, 2019 /PRNewswire/ --BioInvent International AB (OMXS: BINV), focused on the discovery and development of novel and first-in-class immuno-regulatory antibody-based medicines generated by its proprietary platforms, today disclosed a comprehensive program to target... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019
Related companies:  BioInvent International AB

Orexo Publishes the Annual Report for 2018

UPPSALA, Sweden, March 21, 2019 /PRNewswire/ -- Orexo's Annual Report, including the Sustainability Report, for the 2018 fiscal year has been published and can be downloaded on the company's website, Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019
Related companies:  Orexo AB

Muno-Vax Biotechnologies Promotes National Nutrition Month in March

BOCA RATON, Fla., March 21, 2019 /PRNewswire/ -- Muno-Vax Biotechnologies this week urged everyone to re-evaluate their health habits during Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019

Hansa Biopharma Announces Selection of NiceR Lead Candidate

LUND, Sweden, March 21, 2019 /PRNewswire/ --- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the company has selected a lead candidate for clinical development from its NiceR program (Novel IgG... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019

Global Constipation Therapeutics Pipeline Insights 2019 - Analysis by Developmental Stage, Associated indications, Route of Administration and Molecule Type

DUBLIN, March 21, 2019 /PRNewswire/ -- The "Constipation - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Read more ››
By: PR Newswire Association LLC. - 21 Mar 2019

Astanza ReSmooth Diode Laser to be Featured at ASLMS 2019 Learning Lab

DENVER, March 21, 2019 /PRNewswire/ -- The Astanza ReSmooth diode laser was recently... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019
Related companies:  Astanza Laser

Internet Marketing Agency, fishbat, Offers 4 Tips for Pharmaceutical Companies to Build and Maintain Their Customer Service Through Social Media

PATCHOGUE, N.Y., March 21, 2019 /PRNewswire/ -- As part of their ongoing efforts to teach companies how to self-promote across social channels, fishbat, an Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019

Orthobiologics Market to Reach $6.87 Bn, Globally, by 2025 at 4.3% CAGR: AMR

PORTLAND, Oregon, March 21, 2019 /PRNewswire/ -- Allied Market Research recently published a report, titled, Orthobiologics Market by Product (Demineralized Bone Matrix {DBM}, Allograft, Bone Morphogenetic... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019
Related companies:  Allied Market Research

Lannett Purchases $24 Million Of Term Loans In Open Market Transactions

PHILADELPHIA, March 21, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it completed the purchase of approximately $24.2 million principal amount of its Term Loans in open market transactions. The purchases comprised approximately $8.0 million and $16.2 million of... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019
Related companies:  Lannett Company, Inc.

Sprout Pharmaceuticals Presents Important New Addyi Safety and Tolerability Data through Three Alcohol Interaction Studies in Which There Was No Syncope or Orthostatic Hypotension Requiring Medical Attention and No Increase in Adverse Events of Speci

LOS ANGELES, March 21, 2019 /PRNewswire/ -- Sprout Pharmaceuticals, Inc. ("Sprout") today announced the results from three studies evaluating the interaction between and alcohol and Addyi, the first and only FDA approved treatment of acquired, generalized Hypoactive (low) Sexual Desire Disorder... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019
Related companies:  Sprout BioVentures

Selvita to Host Conference Call and Webcast on Thursday, March 28

KRAKOW, Poland, March 21, 2019 /PRNewswire/ -- Selvita (WSE: SLV), a clinical stage company engaged in the research and development of novel cancer therapies as well as provision of drug discovery and development services, today announced that it will report fourth quarter and year end 2018 financial... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019
Related companies:  Selvita Inc.

Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate

JERUSALEM, March 21, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today that all participants have completed their final visit in a Phase 2 clinical trial conducted by several Vaccine Treatment and Evaluation... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019

Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing

BALTIMORE, March 21, 2019 /PRNewswire/ -- Paragon Bioservices, the leading private equity-backed, biologics contract development and manufacturing organization (CDMO) announced today the appointment of Thomas VanCott, Ph.D., as Chief Technology and Strategy Officer (CTSO), along with several... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019

New Insights on an Ancient Disease and Evidence of Effective Therapy

CHARLOTTESVILLE, Va., March 21, 2019 /PRNewswire/ -- AMPEL BioSolutions, a leading data science and technology... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019

Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations

CAMBRIDGE, Mass. and BASEL, Switzerland, March 21, 2019 /PRNewswire/ -- Enzyvant, a biopharmaceutical company focused on developing and commercializing transformative therapies for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019
Related companies:  Enzyvant GmbH

IBA Reports Full Year 2018 Results

Read more ››
By: Nasdaq / GlobenewsWire - 21 Mar 2019
Related companies:  Ion Beam Applications

Addex to Participate in the BIOEurope Spring Conference

Read more ››
By: Nasdaq / GlobenewsWire - 21 Mar 2019
Related companies:  Addex Therapeutics S.A.

Samsung BioLogics Wins 2019 CMO Leadership Awards in All Six Core Categories Three Years in a Row

SEOUL, South Korea, March 21, 2019 /PRNewswire/ -- Samsung BioLogics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, is pleased to announce that Samsung has won CMO Leadership Awards for all six core categories for the third... Read more ››

By: PR Newswire Association LLC. - 21 Mar 2019
Related companies:  Samsung Biologics Co., Ltd.
«  1  2  3  4  5  6  7  8  9  10 11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »

Explore our database of over 50,000 companies